Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06690775 · ClinicalTrials.gov registry record · Phase 2
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by TORL Biotherapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT06690775 is a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that is actively recruiting participants, run by TORL Biotherapeutics. The registered enrollment target is 230 participants, roughly in line with the 253-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT06690775, a Phase 2 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, is actively recruiting participants, sponsored by TORL Biotherapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Conditions Studied
Interventions
- DRUG TORL-1-23
- DRUG Pegfilgrastim (drug)
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Providence St. Jude Medical Center - Fullerton
- UCLA - JCCC Clinical Research Unit - Los Angeles
- Stanford Cancer Center - Palo Alto
- SCRI - Sansum Clinic - Santa Barbara
Minnesota
- SCRI - Minnesota Oncology Hematology, P.A. - Minneapolis
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Arizona
- Mayo Clinic Hospital - Phoenix
- SCRI - Arizona Oncology Associates, PC-HOPE - Tucson
Connecticut
- Smilow Cancer Hospital at Yale - New Haven - New Haven
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- SCRI - Maryland Oncology Hematology, P.A. - Annapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06690775
The ClinicalTrials.gov registry entry for NCT06690775 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 253-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target. The listed sponsor is TORL Biotherapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which TORL-1-23 is the first listed.
NCT06690775 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Minnesota, Arizona.
Frequently Asked Questions
What is clinical trial NCT06690775 about?
NCT06690775 is a clinical study titled "CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.". A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
What is the current status of trial NCT06690775?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2024-11-20. Estimated completion is 2027-12.
What conditions does trial NCT06690775 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal, Endometrioid Ovarian Cancer.
What interventions are being tested in trial NCT06690775?
The interventions under investigation include: TORL-1-23 (DRUG), Pegfilgrastim (drug) (DRUG).
Who is sponsoring clinical trial NCT06690775?
This trial is sponsored by TORL Biotherapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06690775 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.